Literature DB >> 16585086

The role of interleukin-17 during acute rejection after lung transplantation.

B M Vanaudenaerde1, L J Dupont, W A Wuyts, E K Verbeken, I Meyts, D M Bullens, E Dilissen, L Luyts, D E Van Raemdonck, G M Verleden.   

Abstract

Acute rejection (AR) is an important complication that can occur after lung transplantation and constitutes a risk factor for bronchiolitis obliterans syndrome, which is characterised by a neutrophilic airway inflammation. The specific aim of this study was to investigate the role of interleukin (IL)-17, which promotes chemotaxis of neutrophils by inducing IL-8 production, in AR. Cell differentials, mRNA and protein levels were quantified in bronchoalveolar lavages (BALs) taken from patients at 28 and 90 days after lung transplantation. The patient's rejection status was assessed by transbronchial biopsy. An AR was found in nine out of the 26 patients examined, 28 days after transplantation. The number of BAL neutrophils and lymphocytes were increased in these patients. IL-17 mRNA and protein levels in the BAL were increased in patients with AR. Analysis of BAL obtained at day 90 after transplantation, demonstrated that the increase in IL-17 had disappeared, whereas the increase in neutrophils and lymphocytes persisted. These data showed that interleukin-17 is temporarily upregulated in bronchoalveolar lavage during acute rejection. The number of lymphocytes and neutrophils are increased in bronchoalveolar lavage during acute rejection and may persist up to 2 months after acute rejection. These findings suggest that interleukin-17 is important in the pathophysiology of acute lung rejection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16585086     DOI: 10.1183/09031936.06.00019405

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  51 in total

Review 1.  Role of Th17 cells and IL-17 in lung transplant rejection.

Authors:  Rebecca A Shilling; David S Wilkes
Journal:  Semin Immunopathol       Date:  2011-02-01       Impact factor: 9.623

Review 2.  Deciphering the role of Th17 cells in human disease.

Authors:  Cailin Moira Wilke; Keith Bishop; David Fox; Weiping Zou
Journal:  Trends Immunol       Date:  2011-09-28       Impact factor: 16.687

3.  IL-6 and TNF-alpha synergistically inhibit allograft acceptance.

Authors:  Hua Shen; Daniel R Goldstein
Journal:  J Am Soc Nephrol       Date:  2009-04-08       Impact factor: 10.121

Review 4.  Recent progress and new perspectives in studying T cell responses to allografts.

Authors:  A Valujskikh; W M Baldwin; R L Fairchild
Journal:  Am J Transplant       Date:  2010-03-26       Impact factor: 8.086

Review 5.  Interleukin-17 and its expanding biological functions.

Authors:  Sheng Xu; Xuetao Cao
Journal:  Cell Mol Immunol       Date:  2010-04-12       Impact factor: 11.530

Review 6.  Impact of hyperlipidemia on alloimmunity.

Authors:  Jessamyn Bagley; Jin Yuan; John Iacomini
Journal:  Curr Opin Organ Transplant       Date:  2017-02       Impact factor: 2.640

7.  Prevention of acute liver allograft rejection by IL-10-engineered mesenchymal stem cells.

Authors:  J Niu; W Yue; Y Song; Y Zhang; X Qi; Z Wang; B Liu; H Shen; X Hu
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

8.  Interleukin-17 plays a critical role in the acute rejection of intestinal transplantation.

Authors:  Jian-Jun Yang; Fan Feng; Liu Hong; Li Sun; Meng-Bin Li; Ran Zhuang; Feng Pan; Ying-Mei Wang; Wei-Zhong Wang; Guo-Sheng Wu; Hong-Wei Zhang
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

Review 9.  Chronic rejection: a significant role for Th17-mediated autoimmune responses to self-antigens.

Authors:  Vijay Subramanian; Thalachallour Mohanakumar
Journal:  Expert Rev Clin Immunol       Date:  2012-09       Impact factor: 4.473

10.  Codominant Role of Interferon-γ- and Interleukin-17-Producing T Cells During Rejection in Full Facial Transplant Recipients.

Authors:  T J Borges; J T O'Malley; L Wo; N Murakami; B Smith; J Azzi; S Tripathi; J D Lane; E M Bueno; R A Clark; S G Tullius; A Chandraker; C G Lian; G F Murphy; T B Strom; B Pomahac; N Najafian; L V Riella
Journal:  Am J Transplant       Date:  2016-04-07       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.